We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Biogen Defends Patent In Response To Petition For Inter Partes Review

Mealey's (November 14, 2018, 1:07 PM EST) -- ALEXANDRIA, Va. — Contrary to assertions by a petitioner for inter partes review (IPR), a patented regimen for treatment of low-grade, non-Hodgkin’s lymphoma is not obvious, patent owner Biogen Inc. maintains...
To view the full article, register now.